Clinical Trials Directory

Trials / Completed

CompletedNCT05430334

Assess the Influence of Nicotine Flux and Nicotine Form on Subjective Effects Related to Dependency

Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes: Significance of Nicotine Flux to the Rate of Nicotine Delivery and Subjective Effect

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
130 (actual)
Sponsor
American University of Beirut Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Electronic nicotine delivery systems (ENDS) heat and vaporize a nicotine-containing liquid to produce an aerosol that can deliver nicotine to the blood and the brain. ENDS use has increased rapidly in the last decade, especially among youth: over 20% of US high school students are current ENDS users, and there is evidence of nicotine dependence in this population. Federal legislation has been proposed that would restrict ENDS liquid nicotine concentration to make ENDS "significantly less addictive and appealing to youth." However, these and other efforts to curb addiction by limiting nicotine liquid concentration are unlikely to succeed because nicotine emissions from ENDS depend on multiple variables. To achieve the intended public health aims, regulations targeting addiction must focus on nicotine delivery, not nicotine concentration. While nicotine delivery cannot be regulated directly, the rate at which an ENDS emits nicotine, the "nicotine flux", can be regulated and, importantly, predicted based on a few device design and operating variables. However, to date there is no empirical evidence demonstrating the relationship between flux and delivery, nor between flux and the subjective effects that support nicotine dependence. Closing this gap is essential for providing an effective framework for regulating ENDS. At the American University of Beirut, the investigators will assess the relationship between nicotine flux, form, and subjective effects. Participants will use ENDS devices with varying nicotine fluxes and forms. Dependency measures, such as urge to smoke, craving, and abstinence, will be assessed. The outcome will indicate the degree to which nicotine flux/form influence subjective effects related to dependency, puffing intensity, and exposure to toxicants. In summary, this project will provide the empirical evidence needed for public health agencies to use nicotine flux as an encompassing and convenient construct to regulate nicotine delivery from ENDS.

Detailed description

Assess the influence of nicotine flux and nicotine form on subjective effects. At AUB, the investigators will assess subjective effects (e.g. product liking, nicotine craving) and puffing topography for 130 participants who will undergo 5 ENDS use sessions (combinations 1-5) consisting of 2 bouts (10 puffs + 60min ad libitum) with 2 fluxes (16 and 32μg/s) x 2 forms (protonated, freebase) and a 0 nicotine condition. In addition, the investigators will use a state-of-the-art device to sample in situ a fraction of the aerosol generated during each puff to verify actual nicotine flux and form, and measure exposure to pulmonary toxicants (carbonyls). The investigators hypothesize that increasing nicotine flux and protonated nicotine will result in greater reductions of nicotine craving, and lower puffing intensity and carbonyl exposure. In addition, 10 participants that completed the five use sessions will attend the lab for one additional visit with the aim of determining the influence of puff-by-puff variation of ENDS power and liquid composition on puffing behavior and sensory effects. During this visit participants will complete three directed puffing bouts (10 puffs). In each bout, participants will alternate puffs between two identical ENDS devices differing by a single design factor (combinations 6-8).

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTe-liquid 130/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
COMBINATION_PRODUCTe-liquid 230/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
COMBINATION_PRODUCTe-liquid 330/70 PG/VG ratio with nicotine concentration 4mg/ml free base
COMBINATION_PRODUCTe-liquid 430/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
COMBINATION_PRODUCTe-liquid 530/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
COMBINATION_PRODUCTe-liquid 630/70 PG/VG ratio with nicotine concentration 0mg/ml
COMBINATION_PRODUCTe-liquid 7 and e-liquid 8e-liquid 7: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 8: 30/70 PG/VG ratio with nicotine concentration 8mg/ml protonated
COMBINATION_PRODUCTe-liquid 9 and e-liquid 10e-liquid 9: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 10: 70/30 PG/VG ratio with nicotine concentration 4mg/ml protonated

Timeline

Start date
2022-07-13
Primary completion
2025-07-11
Completion
2025-07-11
First posted
2022-06-24
Last updated
2025-07-17

Locations

1 site across 1 country: Lebanon

Source: ClinicalTrials.gov record NCT05430334. Inclusion in this directory is not an endorsement.